ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F20%3A00117585" target="_blank" >RIV/00216224:14740/20:00117585 - isvavai.cz</a>

Alternative codes found

RIV/65269705:_____/20:00072854

Result on the web

<a href="https://www.sciencedirect.com/science/article/pii/S0305737220300645?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0305737220300645?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ctrv.2020.102026" target="_blank" >10.1016/j.ctrv.2020.102026</a>

Result language

angličtina

Original language name

ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias

Original language description

Progress in cancer therapy changed the outcome of many patients and moved therapy from chemotherapy agents to targeted drugs. Targeted drugs already changed the clinical practice in treatment of leukemias, such as imatinib (BCR/ABL inhibitor) in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), ibrutinib (Bruton's tyrosine kinase inhibitor) in chronic lymphocytic leukemia (CLL), venetoclax (BCL2 inhibitor) in CLL and acute myeloid leukemia (AML) or midostaurin (FLT3 inhibitor) in AML. In this review, we focused on DNA damage response (DDR) inhibition, specifically on inhibition of ATR-CHK1 pathway. Cancer cells harbor often defects in different DDR pathways, which render them vulnerable to DDR inhibition. Some DDR inhibitors showed interesting single-agent activity even in the absence of cytotoxic drug especially in cancers with underlying defects in DDR or DNA replication. Almost no mutations were found in ATR and CHEK1 genes in leukemia patients. Together with the fact that ATR-CHK1 pathway is essential for cell development and survival of leukemia cells, it represents a promising therapeutic target for treatment of leukemia. ATR-CHK1 inhibition showed excellent results in preclinical testing in acute and chronic leukemias. However, results in clinical trials are so far insufficient. Therefore, the ongoing and future clinical trials will decide on the success of ATR/CHK1 inhibitors in clinical practice of leukemia treatment.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

CANCER TREATMENT REVIEWS

ISSN

0305-7372

e-ISSN

—

Volume of the periodical

88

Issue of the periodical within the volume

AUG

Country of publishing house

GB - UNITED KINGDOM

Number of pages

12

Pages from-to

102026

UT code for WoS article

000550255600002

EID of the result in the Scopus database

2-s2.0-85086883685